title: [Transarterial chemoembolization with irinotecan (CPT-11) and degradable starch microspheres (DSM) in patients with liver metastases from colorectal cancer].
abstract: We report 27 cases of liver metastases treated with transarterial chemoembolization (TACE) with CPT-11, DSM, and mitomycin C (CPT-DSM therapy). In the 27 patients with liver metastases from colorectal cancer, CPT-DSM therapy was performed 47 times. All of these patients were a contra indication of hepatectomy. We compared a tumor marker before and after the treatment, and measured a serum level of SN-38, which is an active substance of CPT-11 and resolved from CPT-11. Although the level of CPT-11 was wearing off after CPT-DSM therapy, the peak of SN-38 level delayed 1 hour after the infusion. The CEA and CA19-9 levels were decreased to 54.2% and to 45.1% of the level before the treatment, respectively. Nine of the partial response and stable disease patients underwent surgery. The response rate was 59%. A 3-year survival rate was 20%. These results suggest that CPT-DSM therapy is one of the most effective anticancer agents. This TACE can be a feasible therapy for colorectal liver metastases as the first-line therapy.
authors.affiliation: Dept. of Gastrointestinal Surgery, Toho University Omori Medical Center.
authors.forename: Masaru
authors.initials: M
authors.lastname: Tsuchiya
authors.forename: Masashi
authors.initials: M
authors.lastname: Watanabe
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Otsuka
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Yamazaki
authors.forename: Akira
authors.initials: A
authors.lastname: Tamura
authors.forename: Jun
authors.initials: J
authors.lastname: Ishii
authors.forename: Junichi
authors.initials: J
authors.lastname: Koike
authors.forename: Kimihiko
authors.initials: K
authors.lastname: Funahashi
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Teramoto
authors.forename: Hironori
authors.initials: H
authors.lastname: Kaneko
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D007261:Infusions, Intra-Arterial; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008875:Middle Aged; D009367:Neoplasm Staging; D013213:Starch / Q000008:administration & dosage / Q000627:therapeutic use*; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; C083286:degradable starch microspheres; D000077146:Irinotecan; D013213:Starch; D002166:Camptothecin